28/11/2024

Quality Innovation Awards 2024

On 28 November 2024, the CSIC hosted the Quality Innovation Awards, QIA 2024 (Spain phase), which recognise the most outstanding innovations in eight categories.

The winning innovations and accesit awards were evaluated by experts from ANECA and UNIBASQ, convened by the Association of Centres for the Promotion of Excellence. The event was presided over by Elena Cartea, deputy vice-president for scientific and technical areas of the Spanish National Research Council (CSIC); Fernando Sierra, president of the Association of Centres for the Promotion of Excellence (CEX) and Diego Méndez Ruiz, manager of the National Agency for Quality Assessment and Accreditation (ANECA). The ceremony was closed by Elena Mantilla, Director General of Madrid Excelente.

The Quality Innovation Award, QIA is an international competition, created in Finland in 2007 by Excellence Finland, which seeks to promote innovative projects in order to share experiences and increase the competitiveness of the participating countries. The winning Spanish innovations will be competing at a global level to win the Quality Innovation Award, an international edition that will be celebrated in 2025, in Bankok.

Within the eight participating categories, Mikrobiomik has been awarded as ‘Innovation in the health sector’, we congratulate the award-winning organizations in the other categories: the University of Zaragoza, Seguas Aire Comprimido y Frío Industrial, Amadip Esment Fundación, the Diputación Foral de Gipuzkoa, Surphase, Levante Technology Labs and Ence Navia.

Celia Morales González, Technical Director and Head of Quality Control, received the award on behalf of the team. It is another important achievement and recognition for Mikrobiomik, in our daily effort in search of excellence for the development of our innovative investigational drug MBK-01, which has been recognized for its quality and the benefits that it brings both for patients due to its simple dosage and for the health system as an ambulatory option for the treatment of Clostridioides Difficile infection.

Read more:

madridexcelente.com